Listed

Cumberland Pharmaceuticals Inc: Form 10-Q for the period ended Jun 30, 2011

Filed with the SEC on Aug 8, 2011 and accepted by EDGAR at Aug 8, 2011, 17:15 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2011-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2011-04-01 to 2011-06-30$14.4mus-gaap:SalesRevenueNet
Revenue6 months2011-01-01 to 2011-06-30$25.1mus-gaap:SalesRevenueNet
Cost of revenue3 months2011-04-01 to 2011-06-30$1.3mus-gaap:CostOfGoodsSold
Cost of revenue6 months2011-01-01 to 2011-06-30$2.1mus-gaap:CostOfGoodsSold
Research and development3 months2011-04-01 to 2011-06-30$1.0mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2011-01-01 to 2011-06-30$2.0mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2011-04-01 to 2011-06-30$3.6mus-gaap:OperatingIncomeLoss
Operating income6 months2011-01-01 to 2011-06-30$5.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2011-04-01 to 2011-06-30$79.6kus-gaap:InterestExpense
Interest expense6 months2011-01-01 to 2011-06-30$295.6kus-gaap:InterestExpense
Income tax3 months2011-04-01 to 2011-06-30$1.4mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2011-01-01 to 2011-06-30$2.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2011-04-01 to 2011-06-30$2.2mus-gaap:NetIncomeLoss
Net income6 months2011-01-01 to 2011-06-30$2.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2011-04-01 to 2011-06-30$0.11us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2011-01-01 to 2011-06-30$0.14us-gaap:EarningsPerShareDiluted
Basic EPS3 months2011-04-01 to 2011-06-30$0.11us-gaap:EarningsPerShareBasic
Basic EPS6 months2011-01-01 to 2011-06-30$0.14us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2011-04-01 to 2011-06-3020,661,719 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2011-01-01 to 2011-06-3020,719,714 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2011-01-01 to 2011-06-30$4.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2011-01-01 to 2011-06-30$105.8kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases6 months2011-01-01 to 2011-06-30$1.6mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2011-06-30$69.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2011-06-30$84.3mus-gaap:AssetsCurrent
Total assetsAt period end2011-06-30$94.6mus-gaap:Assets
Current liabilitiesAt period end2011-06-30$10.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2011-06-30$13.2mus-gaap:Liabilities
Current portion of debtAt period end2011-06-30$4.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2011-06-30$81.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950123-11-074496. Last ingested by Listed: Nov 14, 2026, 23:39 ET. Listed shows no prices and gives no investment advice.